Juhás Martin, Bachtíková Andrea, Nawrot Daria Elżbieta, Hatoková Paulína, Pallabothula Vinod Sukanth Kumar, Diepoltová Adéla, Janďourek Ondřej, Bárta Pavel, Konečná Klára, Paterová Pavla, Šesták Vít, Zitko Jan
Faculty of Pharmacy in Hradec Králové, Charles University, Akademika Heyrovského 1203, 500 05 Hradec Králové, Czech Republic.
Department of Clinical Microbiology, University Hospital Hradec Králové, Sokolská 581, 500 05 Hradec Králové, Czech Republic.
Pharmaceuticals (Basel). 2022 May 6;15(5):580. doi: 10.3390/ph15050580.
Antimicrobial drug resistance is currently one of the most critical health issues. Pathogens resistant to last-resort antibiotics are increasing, and very few effective antibacterial agents have been introduced in recent years. The promising drug candidates are often discontinued in the primary stages of the drug discovery pipeline due to their unspecific reactivity (PAINS), toxicity, insufficient stability, or low water solubility. In this work, we investigated a series of substituted -oxazolyl- and -thiazolylcarboxamides of various pyridinecarboxylic acids. Final compounds were tested against several microbial species. In general, oxazole-containing compounds showed high activity against mycobacteria, especially (best MIC = 3.13 µg/mL), including the multidrug-resistant strains. Promising activities against various bacterial and fungal strains were also observed. None of the compounds was significantly cytotoxic against the HepG2 cell line. Experimental measurement of lipophilicity parameter log k' and water solubility (log ) confirmed significantly (typically two orders in logarithmic scale) increased hydrophilicity/water solubility of oxazole derivatives in comparison with their thiazole isosteres. Mycobacterial β-ketoacyl-acyl carrier protein synthase III (FabH) was suggested as a probable target by molecular docking and molecular dynamics simulations.
抗菌药物耐药性是当前最关键的健康问题之一。对最后手段抗生素耐药的病原体正在增加,近年来引入的有效抗菌剂很少。有前景的候选药物由于其非特异性反应性(PAINS)、毒性、稳定性不足或水溶性低,往往在药物发现管道的初级阶段就被停用。在这项工作中,我们研究了一系列各种吡啶羧酸的取代恶唑基和噻唑基羧酰胺。对最终化合物进行了几种微生物物种的测试。一般来说,含恶唑的化合物对分枝杆菌显示出高活性,特别是(最佳MIC = 3.13 µg/mL),包括多药耐药菌株。还观察到对各种细菌和真菌菌株有良好活性。没有一种化合物对HepG2细胞系有明显的细胞毒性。亲脂性参数log k'和水溶性(log )的实验测量证实,与它们的噻唑异构体相比,恶唑衍生物的亲水性/水溶性显著增加(通常在对数尺度上相差两个数量级)。通过分子对接和分子动力学模拟表明,分枝杆菌β-酮酰基-酰基载体蛋白合成酶III(FabH)可能是一个靶点。